Pediatr. praxi 2018; 19(6): 322-324 | DOI: 10.36290/ped.2018.063

Is less known human granulocytic anaplasmosis not very significant at the same time?

RNDr. Helena Nejezchlebová, Ph.D., Bc. Renata Horáková, doc. RNDr. Alena Žákovská, Ph.D.
Ústav experimentální biologie, Přírodovědecká fakulta MU, Brno

We provide an overview of less known tick-borne zoonosis, human granulocytic anaplasmosis, with focus on mother and herfetus/child. In addition to the transfer of its bacterial causative agent (Anaplasma phagocytophilum) by ticks, other pathways ofinfection can not be excluded: blood transfusion, skin injury, inhalation of infected blood drops, transplacentar or through breastmilk. Coinfection with other tick-borne diseases may also occur, e. g. with borreliosis. Coinfection contributes to poor conditionof the patient an prolonged duration of clinical manifestations of the disease. A limited number of laboratory-confirmed cases ofanaplasmosis have been described in Europe, but A. phagocytophilum is a cosmopolitan organism, generally considered to be asignificant cause of infection in humans and animals. Increased population mobility and climate warming associated with a risein tick activity or spread of ticks to previously tick-free sites may also result in a higher risk of infection by tick-borne pathogensincluding A. phagocytophilum.

Keywords: human granulocytic anaplasmosis, Anaplasma phagocytophilum, Ixodes ricinus

Published: December 15, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Nejezchlebová H, Horáková R, Žákovská A. Is less known human granulocytic anaplasmosis not very significant at the same time? Pediatr. praxi. 2018;19(6):322-324. doi: 10.36290/ped.2018.063.
Download citation

References

  1. Hulínská D. Lidská ehrlichióza - anaplazmóza. In: Bartůněk a kol. Lymeská borelióza. Grada Praha 2013: 141-149.
  2. http://eol.org/pages/976561/overview [cit. 31-5-2018].
  3. Dumler JS, Choi KS, Garcia-Garcia JC, et al. Human granulocytic anaplasmosis and Anaplasma phagocytophilum. Emerging Infectious Diseases 2005; 11(12): 1828-1834. Go to original source... Go to PubMed...
  4. Dvořáková Heroldová M, Dvořáčková M. Séroprevalence Anaplasma phagocytophilum u pacientů se suspektní lymeskou borreliózou. Epidemiologie, Mikrobiologie, Imunologie 2014; 63(4): 297-302.
  5. Jereb M, Pecaver B, Tomazic J, et al. Severe human granulocytic anaplasmosis transmitted by blood transfusion. Emerging Infectious Diseases 2012; 18(8): 1354-1357. Go to original source... Go to PubMed...
  6. Kalantarpour F, Chowdhury I, Wormser GP, et. al. Survival of the human granulocytic ehrlichiosis agent under refrigeration conditions; Journal of Clinical Microbiology 2000; 38(6), 2398-2399. Go to original source... Go to PubMed...
  7. Bakken JS, Krueth JK, Lund T, et al. Exposure to deer blood may be a cause of human granulocytic ehrlichiosis. Clinical Infectious Diseases 1996; 23(1): 198. Go to original source... Go to PubMed...
  8. Pusterla N, Braun U, Wolfensberger C, et al. Intrauterine infection with Ehrlichia phagocytophila in a cow. Veterinary Record 1997; 141: 101-102. Go to original source... Go to PubMed...
  9. Reppert E, Galind RC, Breshears MA, et al. Demonstration of transplacental transmission of human isolate of Anaplasma phagocytophilum in an experimentally infected sheep. Transboundary and Emerging Diseases 2013; 60(2): 93-96. Go to original source... Go to PubMed...
  10. Horowitz HW, Kilchevsky E., Haber S., et al. Perinatal transmission of the agent of human granulocytic ehrlichiosis. The New England Journal of Medicine 1998; 339(6): 375-378. Go to original source... Go to PubMed...
  11. Muffly T, Chad McCormick T, Cook C, et al. Human granulocytic ehrlichiosis complicating early pregnancy. Infectious Diseases in Obstetrics and Gynecology 2008; 1-3. Go to original source... Go to PubMed...
  12. Aguilera M, Furuseth AM, Giacobbe L, et al. A case of severe human granulocytic anaplasmosis in an immunocompromised pregnant patient. Journal of Medical Cases 2015; 6(6): 282-284. Go to original source...
  13. Dhand A, Nadelman RB, Aguero-Rosenfeld M, et al. Human granulocytic anaplasmosis during pregnancy: case series and literature review. Clinical Infectious Diseases 2007; 45: 589593. Go to original source... Go to PubMed...
  14. Casau NC, Hewins M, Zaleznik DF. Treatment of human granulocytic ehrlichiosis during pregnancy and risk of perinatal transmission. Scandinavian Journal of Infectious Diseases 2002; 34: 853-855. Go to original source... Go to PubMed...
  15. Pusterla N, Hunder J, Wolfensbergen C, et al. Laboratory findings in cows after experimental infection with Ehrlichia phagocytophila. Clinical and Diagnostic Laboratory Immunology 1997; 4(6), 643-647. Go to original source... Go to PubMed...
  16. Dahlgren FS, Mandel EJ, Krebs JW, et al. Increasing incidence of Ehrlichia chaffeensis and Anaplasma phagocytophilum in the United States, 2000-2007. American Journal of Tropical Medicine and Hygiene 2011; 85: 124-131. Go to original source... Go to PubMed...
  17. Tsiodras S, Spanakis N, Spanakos G, et al. Fatal human anaplasmosis associated with macrophage activation syndrome in Greece and the Public Health response. Journal of Infection and Public Health 2017; 10(6): 819-823. Go to original source... Go to PubMed...




Pediatrics for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.